README.md

---
tags:
- sentence-transformers
- sentence-similarity
- feature-extraction
- generated_from_trainer
- dataset_size:216
- loss:MatryoshkaLoss
- loss:MultipleNegativesRankingLoss
base_model: Snowflake/snowflake-arctic-embed-l
widget:
- source_sentence: What types of organizations are eligible to apply for the PAR-25-353
    opportunity titled "National Cooperative Drug/Device Discovery/Development Groups
    (NCDDG) for the Treatment of Mental Disorders"?
  sentences:
  - "PAR-25-353: National Cooperative Drug/Device Discovery/Development Groups (NCDDG)\
    \ for the Treatment of Mental Disorders (U19 Clinical Trial Optional) Section\
    \ III. Eligibility Information\n    \n \n \n \n    1. Eligible Applicants\n  \
    \  \n \n \n   Eligible Organizations\n    \n    Higher Education Institutions\n\
    \    \n \n \n     Public/State Controlled Institutions of Higher Education\n \
    \    \n \n     Private Institutions of Higher Education\n     \n \n \n    The\
    \ following types of Higher Education Institutions are always encouraged to apply\
    \ for NIH support as Public or Private Institutions of Higher Education:\n   \
    \ \n \n \n     Hispanic-serving Institutions\n     \n \n     Historically Black\
    \ Colleges and Universities (HBCUs)\n     \n \n     Tribally Controlled Colleges\
    \ and Universities (TCCUs)\n     \n \n     Alaska Native and Native Hawaiian Serving\
    \ Institutions\n     \n \n     Asian American Native American Pacific Islander\
    \ Serving Institutions (AANAPISIs)\n     \n \n \n    Nonprofits Other Than Institutions\
    \ of Higher Education\n    \n \n \n     Nonprofits with 501(c)(3) IRS Status (Other\
    \ than Institutions of Higher Education)\n     \n \n     Nonprofits without 501(c)(3)\
    \ IRS Status (Other than Institutions of Higher Education)\n     \n \n \n    For-Profit\
    \ Organizations\n    \n \n \n     Small Businesses\n     \n \n     For-Profit\
    \ Organizations (Other than Small Businesses)\n     \n \n \n    Local Governments\n\
    \    \n \n \n     State Governments\n     \n \n     County Governments\n     \n\
    \ \n     City or Township Governments\n     \n \n     Special District Governments\n\
    \     \n \n     Indian/Native American Tribal Governments (Federally Recognized)\n\
    \     \n \n     Indian/Native American Tribal Governments (Other than Federally\
    \ Recognized)\n     \n \n \n \n \n    Federal Governments\n    \n \n \n     Eligible\
    \ Agencies of the Federal Government\n     \n \n     U.S. Territory or Possession\n\
    \     \n \n \n \n \n    Other\n    \n \n \n     Independent School Districts\n\
    \     \n \n     Public Housing Authorities/Indian Housing Authorities\n     \n\
    \ \n     Native American Tribal Organizations (other than Federally recognized\
    \ tribal governments)\n     \n \n     Faith-based or Community-based Organizations\n\
    \     \n \n     Regional Organizations\n     \n \n \n \n   Foreign Organizations\n\
    \    \n \n \n    Non-domestic (non-U.S.) Entities (Foreign Organization)\n   \
    \  \n     are not\n     \n    eligible to apply.\n    \n \n \n \n    Non-domestic\
    \ (non-U.S.) components of U.S. Organizations\n     \n     are not\n     \n  \
    \  eligible to apply.\n    \n \n \n \n    Foreign components, as\n     \n    \
    \ defined in the NIH Grants Policy Statement\n     \n    ,\n     \n     are\n\
    \     \n    allowed.\n    \n \n \n   Required Registrations\n    \n \n     Applicant\
    \ organizations\n     \n \n \n    Applicant organizations must complete and maintain\
    \ the following registrations as described in the\n     \n     How to Apply- Application\
    \ Guide\n     \n    to be eligible to apply for or receive an award. All registrations\
    \ must be completed prior to the application being submitted. Registration can\
    \ take 6 weeks or more, so applicants should begin the registration process as\
    \ soon as possible. Failure to complete registrations in advance of a due date\
    \ is not a valid reason for a late submission, please reference\n     \n     NIH\
    \ Grants Policy Statement Section 2.3.9.2 Electronically Submitted Applications\n\
    \     \n    for additional information.\n    \n \n \n \n      System for Award\
    \ Management (SAM)\n      \n     – Applicants must complete and maintain an active\
    \ registration,\n      \n      which requires renewal at least annually\n    \
    \  \n     . The renewal process may require as much time as the initial registration.\
    \ SAM registration includes the assignment of a Commercial and Government Entity\
    \ (CAGE) Code for domestic organizations which have not already been assigned\
    \ a CAGE Code.\n      \n \n \n        NATO Commercial and Government Entity (NCAGE)\
    \ Code\n        \n       – Foreign organizations must obtain an NCAGE code (in\
    \ lieu of a CAGE code) in order to register in SAM.\n       \n \n       Unique\
    \ Entity Identifier (UEI) - A UEI is issued as part of the SAM.gov registration\
    \ process. The same UEI must be used for all registrations, as well as on the\
    \ grant application.\n       \n \n \n \n \n      eRA Commons\n      \n     - Once\
    \ the unique organization identifier is established, organizations can register\
    \ with eRA Commons in tandem with completing their Grants.gov registration; all\
    \ registrations must be in place by time of submission. eRA Commons requires organizations\
    \ to identify at least one Signing Official (SO) and at least one Program Director/Principal\
    \ Investigator (PD/PI) account in order to submit an application.\n     \n \n\
    \ \n      Grants.gov\n      \n     – Applicants must have an active SAM registration\
    \ in order to complete the Grants.gov registration.\n     \n \n \n \n     Program\
    \ Directors/Principal Investigators (PD(s)/PI(s))\n     \n \n \n    All PD(s)/PI(s)\
    \ must have an eRA Commons account.  PD(s)/PI(s) should work with their organizational\
    \ officials to either create a new account or to affiliate their existing account\
    \ with the applicant organization in eRA Commons. If the PD/PI is also the organizational\
    \ Signing Official, they must have two distinct eRA Commons accounts, one for\
    \ each role. Obtaining an eRA Commons account can take up to 2 weeks.\n    \n\
    \ \n \n   Eligible Individuals (Program Director/Principal Investigator)\n   \
    \ \n    Any individual(s) with the skills, knowledge, and resources necessary\
    \ to carry out the proposed research as the Program Director(s)/Principal Investigator(s)\
    \ (PD(s)/PI(s)) is invited to work with his/her organization to develop an application\
    \ for support.\n    \n \n    For institutions/organizations proposing multiple\
    \ PDs/PIs, visit the Multiple Program Director/Principal Investigator Policy and\
    \ submission details in the Senior/Key Person Profile (Expanded) Component of\
    \ the\n     \n     How to Apply - Application Guide\n     \n    .\n    \n \n \n\
    \ \n    An NIH intramural scientist may not serve as the PD/PI of an NCDDG but\
    \ may participate as a research collaborator or consultant (see\n     \n \n \n\
    \     Section IV.7\n     \n \n \n    for more information).\n    \n \n \n \n \
    \   2. Cost Sharing\n    \n \n    This NOFO does not require cost sharing as defined\
    \ in the\n     \n     NIH Grants Policy Statement\n     \n \n     Section 1.2-\
    \ Definitions of Terms.\n     \n \n \n \n \n    3. Additional Information on Eligibility\n\
    \    \n \n    Number of Applications\n    \n \n \n \n    Applicant organizations\
    \ may submit more than one application, provided that each application is scientifically\
    \ distinct.\n    \n \n    The NIH will not accept duplicate or highly overlapping\
    \ applications under review at the same time per\n     \n     NIH Grants Policy\
    \ Statement Section 2.3.7.4 Submission of Resubmission Application\n     \n  \
    \  . This means that the NIH will not accept:\n    \n \n \n     A new (A0) application\
    \ that is submitted before issuance of the summary statement from the review of\
    \ an overlapping new (A0) or resubmission (A1) application.\n     \n \n     A\
    \ resubmission (A1) application that is submitted before issuance of the summary\
    \ statement from the review of the previous new (A0) application.\n     \n \n\
    \     An application that has substantial overlap with another application pending\
    \ appeal of initial peer review (see\n      \n      NIH Grants Policy Statement\
    \ 2.3.9.4 Similar, Essentially Identical, or Identical Applications\n      \n\
    \     )."
  - "RFA-DK-26-009: New Investigator Gateway Awards for Collaborative T1D Research\
    \ (R03 Clinical Trial Not Allowed) Section VI. Award Administration Information\n\
    \    \n \n \n \n    1. Award Notices\n    \n \n    A Notice of Award (NoA) is\
    \ the official authorizing document notifying the applicant that an award has\
    \ been made and that funds may be requested from the designated HHS payment system\
    \ or office. The NoA is signed by the Grants Management Officer and emailed to\
    \ the recipient’s business official.\n    \n \n    In accepting the award, the\
    \ recipient agrees that any activities under the award are subject to all provisions\
    \ currently in effect or implemented during the period of the award, other Department\
    \ regulations and policies in effect at the time of the award, and applicable\
    \ statutory provisions.\n    \n \n    Recipients must comply with any funding\
    \ restrictions described in\n     \n     Section IV.6. Funding Restrictions\n\
    \     \n    . Any pre-award costs incurred before receipt of the NoA are at the\
    \ applicant's own risk.  For more information on the Notice of Award, please refer\
    \ to the\n     \n     NIH Grants Policy Statement Section 5. The Notice of Award\n\
    \     \n    and NIH Grants & Funding website, see\n     \n     Award Process.\n\
    \     \n \n \n \n \n    Institutional Review Board or Independent Ethics Committee\
    \ Approval: Recipient institutions must ensure that protocols are reviewed by\
    \ their IRB or IEC. To help ensure the safety of participants enrolled in NIH-funded\
    \ studies, the recipient must provide NIH copies of documents related to all major\
    \ changes in the status of ongoing protocols.\n    \n \n \n \n    2. Administrative\
    \ and National Policy Requirements\n    \n \n    The following Federal wide and\
    \ HHS-specific policy requirements apply to awards funded through NIH:\n    \n\
    \ \n \n     The rules listed at\n      \n      2 CFR Part 200\n      \n     ,\
    \ Uniform Administrative Requirements, Cost Principles, and Audit Requirements\
    \ for Federal Awards.\n     \n \n     All NIH grant and cooperative agreement\
    \ awards include the\n      \n      NIH Grants Policy Statement\n      \n    \
    \ as part of the terms and conditions in the Notice of Award (NoA). The NoA includes\
    \ the requirements of this NOFO. For these terms of award, see the\n      \n \
    \     NIH Grants Policy Statement Part II: Terms and Conditions of NIH Grant Awards,\
    \ Subpart A: General\n      \n     and\n      \n      Part II: Terms and Conditions\
    \ of NIH Grant Awards, Subpart B: Terms and Conditions for Specific Types of Grants,\
    \ Recipients, and Activities\n      \n     .\n     \n \n     If a recipient receives\
    \ an award, the recipient must follow all applicable nondiscrimination laws. The\
    \ recipient agrees to this when registering in SAM.gov. The recipient must also\
    \ submit an Assurance of Compliance (\n      \n      HHS-690\n      \n     ).\
    \ To learn more, see the\n      \n      Laws and Regulations Enforced by the HHS\
    \ Office for Civil Rights website\n      \n     .\n      \n \n       HHS recognizes\
    \ that NIH research projects are often limited in scope for many reasons that\
    \ are nondiscriminatory, such as the principal investigator’s scientific interest,\
    \ funding limitations, recruitment requirements, and other considerations. Thus,\
    \ criteria in research protocols that target or exclude certain populations are\
    \ warranted where nondiscriminatory justifications establish that such criteria\
    \ are appropriate with respect to the health or safety of the subjects, the scientific\
    \ study design, or the purpose of the research. For additional guidance regarding\
    \ how the provisions apply to NIH grant programs, please contact the Scientific/Research\
    \ Contact that is identified in Section VII under Agency Contacts of this NOFO.\n\
    \       \n \n \n \n \n    All federal statutes and regulations relevant to federal\
    \ financial assistance, including those highlighted in\n     \n     NIH Grants\
    \ Policy Statement Section 4 Public Policy Requirements, Objectives and Other\
    \ Appropriation Mandates.\n     \n \n \n    Recipients are responsible for ensuring\
    \ that their activities comply with all applicable federal regulations.  NIH may\
    \ terminate awards under certain circumstances.  See\n     \n     2 CFR Part 200.340\
    \ Termination\n     \n    and\n     \n     NIH Grants Policy Statement Section\
    \ 8.5.2 Remedies for Noncompliance or Enforcement Actions: Suspension, Termination,\
    \ and Withholding of Support\n     \n    .\n    \n \n    Successful recipients\
    \ under this NOFO agree that:\n    \n \n    Where the award funding involves implementing,\
    \ acquiring, or upgrading health IT for activities by any funded entity, recipients\
    \ and subrecipient(s) are required to: Use health IT that meets standards and\
    \ implementation specifications adopted in 45 CFR part 170, Subpart B, if such\
    \ standards and implementation specifications can support the activity.  Visit\n\
    \     \n     https://www.ecfr.gov/current/title-45/subtitle-A/subchapter-D/part-170/subpart-B\n\
    \     \n    to learn more.\n    \n \n    Where the award funding involves implementing,\
    \ acquiring, or upgrading health IT for activities by eligible clinicians in ambulatory\
    \ settings, or hospitals, eligible under Sections 4101, 4102, and 4201 of the\
    \ HITECH Act, use health IT certified under the ONC Health IT Certification Program\
    \ if certified technology can support the activity. Visit\n     \n     https://www.healthit.gov/topic/certification-ehrs/certification-health-it\n\
    \     \n    to learn more.\n    \n \n    Pursuant to the Cybersecurity Act of\
    \ 2015, Div. N, § 405, Pub. Law 114-113, 6 USC § 1533(d), the HHS Secretary has\
    \ established a common set of voluntary, consensus-based, and industry-led guidelines,\
    \ best practices, methodologies, procedures, and processes.\n    \n \n    Successful\
    \ recipients under this NOFO agree that:\n    \n \n    When recipients, subrecipients,\
    \ or third-party entities have:\n    \n \n \n     ongoing and consistent access\
    \ to HHS owned or operated information or operational technology systems; and\n\
    \     \n \n     receive, maintain, transmit, store, access, exchange, process,\
    \ or utilize personal identifiable information (PII) or personal health information\
    \ (PHI) obtained from the awarding HHS agency for the purposes of executing the\
    \ award.\n     \n \n \n    Recipients shall develop plans and procedures, modeled\
    \ after the\n     \n     NIST Cybersecurity framework\n     \n    , to protect\
    \ HHS systems and data. Please refer to\n     \n     NIH Post-Award Monitoring\
    \ and Reporting\n     \n    for additional information.\n    \n \n \n   Cooperative\
    \ Agreement Terms and Conditions of Award\n    \n    Not Applicable.\n    \n \n\
    \ \n   3. Data Management and Sharing\n    \n    Consistent with the 2023 NIH\
    \ Policy for Data Management and Sharing, when data management and sharing is\
    \ applicable to the award, recipients will be required to adhere to the Data Management\
    \ and Sharing requirements as outlined in the\n     \n     NIH Grants Policy Statement\n\
    \     \n    . Upon the approval of a Data Management and Sharing Plan, it is required\
    \ for recipients to implement the plan as described.\n    \n \n \n \n    4. Reporting\n\
    \    \n \n    When multiple years are involved, recipients will be required to\
    \ submit the\n     \n     Research Performance Progress Report (RPPR)\n     \n\
    \    annually and financial statements as required in the\n     \n     NIH Grants\
    \ Policy Statement Section 8.4.1 Reporting.\n     \n    To learn more about post-award\
    \ monitoring and reporting, see the NIH Grants & Funding website, see\n     \n\
    \     Post-Award Monitoring and Reporting\n     \n    .\n    \n \n \n \n    A\
    \ final RPPR, invention statement, and the expenditure data portion of the Federal\
    \ Financial Report are required for closeout of an award, as described in the\n\
    \     \n     NIH Grants Policy Statement Section 8.6 Closeout\n     \n    . NIH\
    \ NOFOs outline intended research goals and objectives. Post award, NIH will review\
    \ and measure performance based on the details and outcomes that are shared within\
    \ the RPPR, as described at 2 CFR Part 200.301."
  - "RFA-HL-26-011: Leadership and Coordination Center (LACC) for the MACS/WIHS Combined\
    \ Cohort Study (MWCCS) (U01 Clinical Trials Not Allowed) Section II. Award Information\n\
    \    \n \n \n   Funding Instrument\n    \n    Cooperative Agreement: A financial\
    \ assistance mechanism used when there will be substantial Federal scientific\
    \ or programmatic involvement. Substantial involvement means that, after award,\
    \ NIH scientific or program staff will assist, guide, coordinate, or participate\
    \ in project activities. See Section VI.2 for additional information about the\
    \ substantial involvement for this NOFO.\n    \n \n \n   Application Types Allowed\n\
    \   New\n    \n \n \n \n    The\n     \n     OER Glossary\n     \n    and the\
    \ How to Apply Application Guide provide details on these application types. Only\
    \ those application types listed here are allowed for this NOFO.\n    \n \n \n\
    \   Clinical Trial?\n    \n    Not Allowed: Only accepting applications that do\
    \ not propose clinical trials.\n    \n \n \n \n \n     Need help determining whether\
    \ you are doing a clinical trial?\n     \n \n \n \n   Funds Available and Anticipated\
    \ Number of Awards\n    \n    The following NIH components intend to commit an\
    \ estimated total of $3 million to fund a single award in FY 2026:\n    \n \n\
    \    NHLBI, $1.37 million\n    \n \n    NIAID, $0.30 million\n    \n \n    NIMH, $0.30\
    \ million\n    \n \n    NCI, $0.35 million\n    \n \n    NIA, $0.19 million\n\
    \    \n \n    NIDA, $0.15 million\n    \n \n    NICHD, $0.13 million\n    \n \n\
    \    NIDCR, $0.07 million\n    \n \n    NIMHD, $0.04 million\n    \n \n    NIAAA, $0.03\
    \ million\n    \n \n    NINR, $0.03 million\n    \n \n    ORWH, $0.03 million\n\
    \    \n \n    NIDCD, $0.02 million\n    \n \n \n   Award Budget\n    \n    Application\
    \ budgets may not exceed direct costs of $2 million per year in Fiscal Years 2026\
    \ through 2031.\n    \n \n \n   Award Project Period\n    \n    6 years\n    \n\
    \ This variable defines that we need to start a new row.  \n \n \n \n    NIH grants\
    \ policies as described in the\n     \n     NIH Grants Policy Statement\n    \
    \ \n    will apply to the applications submitted and awards made from this NOFO."
- source_sentence: How does the title of opportunity ID [insert ID] align with the
    strategic goals of the Department of Health and Human Services?
  sentences:
  - Department of Health and Human Services
  - "RFA-DK-26-007: Collaborative Research Using Biosamples and/or Data from Type\
    \ 1 Diabetes Clinical Studies (R01 - Clinical Trial Not Allowed) Section II. Award\
    \ Information\n    \n \n \n   Funding Instrument\n    \n    Grant: A financial\
    \ assistance mechanism providing money, property, or both to an eligible entity\
    \ to carry out an approved project or activity.\n    \n \n \n   Application Types\
    \ Allowed\n   New\n    \n   Resubmission - Resubmission applications from\n  \
    \  \n    RFA-DK-22-021\n    \n   and from the current active NOFO RFA-DK-26-007\
    \ may be submitted in response to this NOFO.\n    \n \n \n \n    The\n     \n\
    \     OER Glossary\n     \n    and the How to Apply Application Guide provide\
    \ details on these application types. Only those application types listed here\
    \ are allowed for this NOFO.\n    \n \n \n   Clinical Trial?\n    \n    Not Allowed:\
    \ Only accepting applications that do not propose clinical trials.\n    \n \n\
    \ \n \n \n     Need help determining whether you are doing a clinical trial?\n\
    \     \n \n \n \n   Funds Available and Anticipated Number of Awards\n    \n \
    \   NIDDK intends to commit $5.5 million in Fiscal Year 2026 to fund 3-4 awards\
    \ and $5.5 million in FY 27 to fund 3-4 awards. The number of awards is contingent\
    \ upon the submission of a sufficient number of meritorious applications.\n  \
    \  \n \n \n   Award Budget\n    \n    Application budgets are limited to no more\
    \ than $1,200,000 direct costs per year, exclusive of facilities and administrative\
    \ (F&A) costs. Budgets are expected to reflect the actual needs of the proposed\
    \ project.\n    \n \n \n   Award Project Period\n    \n    The maximum project\
    \ period is 3 years.\n    \n This variable defines that we need to start a new\
    \ row.  \n \n \n \n    NIH grants policies as described in the\n     \n     NIH\
    \ Grants Policy Statement\n     \n    will apply to the applications submitted\
    \ and awards made from this NOFO."
  - "RFA-DK-26-009: New Investigator Gateway Awards for Collaborative T1D Research\
    \ (R03 Clinical Trial Not Allowed) Section IV. Application and Submission Information\n\
    \    \n \n \n \n    1. Requesting an Application Package\n    \n \n    The application\
    \ forms package specific to this opportunity must be accessed through ASSIST,\
    \ Grants.gov Workspace or an institutional system-to-system solution. Links to\
    \ apply using ASSIST or Grants.gov Workspace are available in Part 1 of this NOFO.\
    \ See your administrative office for instructions if you plan to use an institutional\
    \ system-to-system solution.\n    \n \n \n \n    2. Content and Form of Application\
    \ Submission\n    \n \n    It is critical that applicants follow the instructions\
    \ in the Research (R) Instructions in the\n     \n     How to Apply - Application\
    \ Guide\n     \n    except where instructed in this notice of funding opportunity\
    \ to do otherwise. Conformance to the requirements in the Application Guide is\
    \ required and strictly enforced. Applications that are out of compliance with\
    \ these instructions may be delayed or not accepted for review.\n    \n \n \n\
    \ \n    Letter of Intent\n    \n \n    Although a letter of intent is not required,\
    \ is not binding, and does not enter into the review of a subsequent application,\
    \ the information that it contains allows IC staff to estimate the potential review\
    \ workload and plan the review.\n    \n \n    By the date listed in\n     \n \
    \    Part 1. Overview Information\n     \n    , prospective applicants are asked\
    \ to submit a letter of intent that includes the following information:\n    \n\
    \ \n \n     Descriptive title of proposed activity\n     \n \n     Name(s), address(es),\
    \ and telephone number(s) of the PD(s)/PI(s)\n     \n \n     Names of other key\
    \ personnel\n     \n \n     Participating institution(s)\n     \n \n     Number\
    \ and title of this funding opportunity\n     \n \n \n    The letter of intent\
    \ should be sent to:\n    \n \n    John Connaughton, Ph.D.\n     \n    Chief,\
    \ Scientific Review Branch\n     \n    National Institute of Diabetes and Digestive\
    \ and Kidney Diseases (NIDDK)\n     \n    Telephone: 301-594-7797\n     \n   \
    \ Email:\n     \n \n      [email protected]\n      \n \n \n \n \n \n    Page Limitations\n\
    \    \n \n    All page limitations described in the\n     \n     How to Apply-\
    \ Application Guide\n     \n    and the\n     \n     Table of Page Limits\n  \
    \   \n    must be followed.\n    \n \n \n   Instructions for Application Submission\n\
    \    \n    The following section supplements the instructions found in the\n \
    \    \n     How to Apply- Application Guide\n     \n    and should be used for\
    \ preparing an application to this NOFO.\n    \n \n \n \n    SF424(R&R) Cover\n\
    \    \n \n    All instructions in the\n     \n \n      How to Apply - Application\
    \ Guide\n      \n \n    must be followed.\n    \n \n \n \n    SF424(R&R) Project/Performance\
    \ Site Locations\n    \n \n    All instructions in the How to Apply- Application\
    \ Guide must be followed.\n    \n \n \n \n    SF424(R&R) Other Project Information\n\
    \    \n \n    All instructions in the How to Apply- Application Guide must be\
    \ followed.\n    \n \n \n \n \n     Other Attachments:\n     \n \n \n \n     Proposed\
    \ Affiliation Letter\n     \n    : Name the PDF formatted letter \"Proposed_Affiliation_Ltr.pdf\"\
    . Applications must include a one page letter that includes a brief statement\
    \ identifying the specific NIDDK consortium or network that is within scope of\
    \ the proposed aims. In addition, the applicant must outline in the letter how\
    \ the objectives and design of the application are related to, but distinct from,\
    \ ongoing studies in the consortium or network of interest, and describe how developing\
    \ a relationship with the chosen consortium or network would be expected to facilitate\
    \ the applicant's research and career goals. Applications that lack the proposed\
    \ Affiliation Letter are considered incomplete and will not be peer reviewed.\n\
    \    \n \n \n \n    SF424(R&R) Senior/Key Person Profile\n    \n \n    All instructions\
    \ in the How to Apply- Application Guide must be followed.\n    \n \n \n \n  \
    \  R&R or Modular Budget\n    \n \n    All instructions in the How to Apply- Application\
    \ Guide must be followed.\n    \n \n \n \n    Applicants should also follow these\
    \ additional instructions:\n    \n \n    Applicants should budget for travel to\
    \ one meeting of the proposed affiliated consortium or network per year. Except\
    \ in unusual circumstances, only the PD/PI may be supported by R03 funds to travel\
    \ to consortium meetings. There is no specific line item in which to list travel\
    \ costs ($2000/year) in the modular budget format; instead, the proposed travel\
    \ should be described in the budget justification section.\n    \n \n \n \n  \
    \  R&R Subaward Budget\n    \n \n    All instructions in the How to Apply-Application\
    \ Guide must be followed.\n    \n \n \n \n    PHS 398 Cover Page Supplement\n\
    \    \n \n    All instructions in the How to Apply- Application Guide must be\
    \ followed.\n    \n \n \n \n    PHS 398 Research Plan\n    \n \n    All instructions\
    \ in the How to Apply- Application Guide must be followed, with the following\
    \ additional instructions:\n    \n \n \n \n \n     Resource Sharing Plan\n   \
    \  \n    : Individuals are required to comply with the instructions for the Resource\
    \ Sharing Plans as provided in the How to Apply- Application Guide.\n    \n \n\
    \ \n \n \n     Protocol, tool and reagent sharing\n     \n    : The applicant\
    \ should discuss plans for sharing and distribution of non-data resources that\
    \ will be generated by the proposed project, including models, protocols, computational\
    \ tools, biomaterials, and reagents. As one of the essential goals of the Gateway program\
    \ is to support high impact advances, NIDDK intends that tools and reagents generated\
    \ by the Gateway program will be made broadly available and distributed at minimal\
    \ cost, and without undue intellectual property constraints, so that they can\
    \ be as widely used as possible, thus enabling rapid downstream applications for\
    \ the reagents by the larger scientific community. Applicants are expected to\
    \ register resources supported by this NOFO with the NIDDK Information Network\
    \ (dkNET) at\n     \n     https://dknet.org/\n     \n    and use Research Resource\
    \ Identifiers (RRID) assigned through dkNET in any publication supported by this\
    \ NOFO. Applicants should also be familiar with the NIH statements regarding intellectual\
    \ property of resources developed with Federal funds\n     \n     (\n     \n \
    \   NIH Research Tools Policy (\n     \n \n      https://grants.nih.gov/grants/intell-property_64FR72090.pdf\n\
    \      \n \n    ) and other related NIH sharing policies at\n     \n \n      http://sharing.\n\
    \      \n     nih.gov\n     \n    .\n    \n \n \n \n \n     Other Plan(s):\n \
    \    \n \n \n    All instructions in the How to Apply-Application Guide must be\
    \ followed, with the following additional instructions:\n    \n \n \n \n \n  \
    \   All applicants planning research (funded or conducted in whole or in part\
    \ by NIH) that results in the generation of scientific data are required to comply\
    \ with the instructions for the Data Management and Sharing Plan.\n     \n \n\
    \ \n \n \n \n     Appendix:\n     \n    Only limited Appendix materials are allowed.\
    \ Follow all instructions for the Appendix as described in the How to Apply- Application\
    \ Guide.\n    \n \n \n     No publications or other material, with the exception\
    \ of blank questionnaires or blank surveys, may be included in the Appendix.\n\
    \     \n \n \n \n \n    PHS Human Subjects and Clinical Trials Information\n \
    \   \n \n    When involving human subjects research, clinical research, and/or\
    \ NIH-defined clinical trials (and when applicable, clinical trials research experience)\
    \ follow all instructions for the PHS Human Subjects and Clinical Trials Information\
    \ form in the How to Apply- Application Guide, with the following additional instructions:\n\
    \    \n \n    If you answered “Yes” to the question “Are Human Subjects Involved?”\
    \ on the R&R Other Project Information form, you must include at least one human\
    \ subjects study record using the\n     \n     Study Record: PHS Human Subjects\
    \ and Clinical Trials Information\n     \n    form or\n     \n     Delayed Onset\
    \ Study\n     \n    record.\n    \n \n \n     Study Record: PHS Human Subjects\
    \ and Clinical Trials Information\n     \n \n \n    All instructions in the How\
    \ to Apply- Application Guide must be followed.\n    \n \n \n \n \n     Delayed\
    \ Onset Study\n     \n \n \n    Note:\n     \n     Delayed onset\n     \n    does\
    \ NOT apply to a study that can be described but will not start immediately (i.e.,\
    \ delayed start). All instructions in the How to Apply- Application Guide must\
    \ be followed.\n    \n \n \n \n    PHS Assignment Request Form\n    \n \n    All\
    \ instructions in the How to Apply- Application Guide must be followed.\n    \n\
    \ \n \n \n    3. Unique Entity Identifier and System for Award Management (SAM)\n\
    \    \n \n    See Part 2. Section III.1 for information regarding the requirement\
    \ for obtaining a unique entity identifier and for completing and maintaining\
    \ active registrations in System for Award Management (SAM), NATO Commercial and\
    \ Government Entity (NCAGE) Code (if applicable), eRA Commons, and Grants.gov\n\
    \    \n \n \n \n    4. Submission Dates and Times\n    \n \n    Part I. contains\
    \ information about Key Dates and times. Applicants are encouraged to submit applications\
    \ before the due date to ensure they have time to make any application corrections\
    \ that might be necessary for successful submission. When a submission date falls\
    \ on a weekend or\n     \n     Federal holiday\n     \n    , the application deadline\
    \ is automatically extended to the next business day.\n    \n \n    Organizations\
    \ must submit applications to\n     \n     Grants.gov\n     \n    (the online\
    \ portal to find and apply for grants across all Federal agencies). Applicants\
    \ must then complete the submission process by tracking the status of the application\
    \ in the\n     \n     eRA Commons\n     \n    , NIH’s electronic system for grants\
    \ administration. NIH and Grants.gov systems check the application against many\
    \ of the application instructions upon submission. Errors must be corrected and\
    \ a changed/corrected application must be submitted to Grants.gov on or before\
    \ the application due date and time.  If a Changed/Corrected application is submitted\
    \ after the deadline, the application will be considered late. Applications that\
    \ miss the due date and time are subjected to the\n     \n     NIH Grants Policy\
    \ Statement Section 2.3.9.2 Electronically Submitted Applications\n     \n   \
    \ .\n    \n \n \n     Applicants are responsible for viewing their application\
    \ before the due date in the eRA Commons to ensure accurate and successful submission.\n\
    \     \n \n \n    Information on the submission process and a definition of on-time\
    \ submission are provided in the How to Apply-Application Guide.\n    \n \n \n\
    \ \n    5. Intergovernmental Review (E.O. 12372)\n    \n \n    This initiative\
    \ is not subject to\n     \n     intergovernmental review.\n     \n \n \n \n \n\
    \    6. Funding Restrictions\n    \n \n    All NIH awards are subject to the terms\
    \ and conditions, cost principles, and other considerations described in the\n\
    \     \n     NIH Grants Policy Statement\n     \n    .\n    \n \n    Pre-award\
    \ costs are allowable only as described in the\n     \n     NIH Grants Policy\
    \ Statement Section 7.9.1 Selected Items of Cost.\n     \n \n \n \n   7. Other\
    \ Submission Requirements and Information\n    \n    Applications must be submitted\
    \ electronically following the instructions described in the How to Apply Application\
    \ Guide. Paper applications will not be accepted.\n    \n \n    Applicants must\
    \ complete all required registrations before the application due date. Section\
    \ III. Eligibility Information contains information about registration.\n    \n\
    \ \n    For assistance with your electronic application or for more information\
    \ on the electronic submission process, visit\n     \n     How to Apply – Application\
    \ Guide\n     \n    . If you encounter a system issue beyond your control that\
    \ threatens your ability to complete the submission process on-time, you must\
    \ follow the\n     \n     Dealing with System Issues\n     \n    guidance. For\
    \ assistance with application submission, contact the Application Submission Contacts\
    \ in Section VII.\n    \n \n \n     Important reminders:\n     \n \n \n    All\
    \ PD(s)/PI(s) must include their eRA Commons ID in the Credential field of the\
    \ Senior/Key Person Profile form\n     \n     .\n     \n    Failure to register\
    \ in the Commons and to include a valid PD/PI Commons ID in the credential field\
    \ will prevent the successful submission of an electronic application to NIH.\
    \ See Section III of this NOFO for information on registration requirements.\n\
    \    \n \n    The applicant organization must ensure that the unique entity identifier\
    \ provided on the application is the same identifier used in the organization’s\
    \ profile in the eRA Commons and for the System for Award Management. Additional\
    \ information may be found in the How to Apply Application Guide.\n    \n \n \
    \   See\n     \n     more tips\n     \n    for avoiding common errors.\n    \n\
    \ \n \n \n    Upon receipt, applications will be evaluated for completeness and\
    \ compliance with application instructions by the Center for Scientific Review\
    \ and responsiveness by NIDDK.  Applications that are incomplete, non-compliant,\
    \ and/or nonresponsive will not be reviewed.\n    \n \n \n   Mandatory Disclosure\n\
    \    \n    Recipients or subrecipients must submit any information related to\
    \ violations of federal criminal law involving fraud, bribery, or gratuity violations\
    \ potentially affecting the federal award. See Mandatory Disclosures,\n     \n\
    \     2 CFR 200.113\n     \n    and\n     \n     NIH Grants Policy Statement Section\
    \ 4.1.35\n     \n    .\n    \n \n    Send written disclosures to the NIH Chief\
    \ Grants Management Officer listed on the Notice of Award for the IC that funded\
    \ the award and to the\n     \n     HHS Office of Inspector Grant Self Disclosure\
    \ Program\n     \n    at\n     \n \n      [email protected]\n      \n \n    .\n\
    \    \n \n \n \n    Post Submission Materials\n    \n \n    Applicants are required\
    \ to follow the instructions for post-submission materials, as described in\n\
    \     \n     the policy"
- source_sentence: What are the main objectives of the Leadership and Coordination
    Center (LACC) for the MACS/WIHS Combined Cohort Study (MWCCS) as outlined in opportunity
    id RFA-HL-26-011?
  sentences:
  - 'RFA-HL-26-011: Leadership and Coordination Center (LACC) for the MACS/WIHS Combined
    Cohort Study (MWCCS) (U01 Clinical Trials Not Allowed) Part 2. Full Text of Announcement'
  - "PAR-25-353: National Cooperative Drug/Device Discovery/Development Groups (NCDDG)\
    \ for the Treatment of Mental Disorders (U19 Clinical Trial Optional) Section\
    \ VIII. Other Information\n    \n \n \n \n    Recently issued trans-NIH\n    \
    \ \n     policy notices\n     \n    may affect your application submission. A\
    \ full list of policy notices published by NIH is provided in the\n     \n   \
    \  NIH Guide for Grants and Contracts\n     \n    . All awards are subject to\
    \ the terms and conditions, cost principles, and other considerations described\
    \ in the\n     \n     NIH Grants Policy Statement\n     \n    .\n    \n \n \n\
    \   Authority and Regulations\n    \n    Awards are made under the authorization\
    \ of Sections 301 and 405 of the Public Health Service Act as amended (42 USC\
    \ 241 and 284) and under Federal Regulations 42 CFR Part 52 and 2 CFR Part 200.\n\
    \    \n  end row  \n \n \n \n \n    Weekly TOC for this Announcement\n    \n \n\
    \ \n    NIH Funding Opportunities and Notices\n    \n \n \n \n \n \n \n \n \n\
    \ \n \n \n \n  Department of Health\n   \n  and Human Services (HHS)\n   \n \n\
    \ \n \n   NIH... Turning Discovery Into Health\n    \n    ®"
  - "PAR-25-353: National Cooperative Drug/Device Discovery/Development Groups (NCDDG)\
    \ for the Treatment of Mental Disorders (U19 Clinical Trial Optional) Section\
    \ III. Eligibility Information\n    \n \n \n \n    1. Eligible Applicants\n  \
    \  \n \n \n   Eligible Organizations\n    \n    Higher Education Institutions\n\
    \    \n \n \n     Public/State Controlled Institutions of Higher Education\n \
    \    \n \n     Private Institutions of Higher Education\n     \n \n \n    The\
    \ following types of Higher Education Institutions are always encouraged to apply\
    \ for NIH support as Public or Private Institutions of Higher Education:\n   \
    \ \n \n \n     Hispanic-serving Institutions\n     \n \n     Historically Black\
    \ Colleges and Universities (HBCUs)\n     \n \n     Tribally Controlled Colleges\
    \ and Universities (TCCUs)\n     \n \n     Alaska Native and Native Hawaiian Serving\
    \ Institutions\n     \n \n     Asian American Native American Pacific Islander\
    \ Serving Institutions (AANAPISIs)\n     \n \n \n    Nonprofits Other Than Institutions\
    \ of Higher Education\n    \n \n \n     Nonprofits with 501(c)(3) IRS Status (Other\
    \ than Institutions of Higher Education)\n     \n \n     Nonprofits without 501(c)(3)\
    \ IRS Status (Other than Institutions of Higher Education)\n     \n \n \n    For-Profit\
    \ Organizations\n    \n \n \n     Small Businesses\n     \n \n     For-Profit\
    \ Organizations (Other than Small Businesses)\n     \n \n \n    Local Governments\n\
    \    \n \n \n     State Governments\n     \n \n     County Governments\n     \n\
    \ \n     City or Township Governments\n     \n \n     Special District Governments\n\
    \     \n \n     Indian/Native American Tribal Governments (Federally Recognized)\n\
    \     \n \n     Indian/Native American Tribal Governments (Other than Federally\
    \ Recognized)\n     \n \n \n \n \n    Federal Governments\n    \n \n \n     Eligible\
    \ Agencies of the Federal Government\n     \n \n     U.S. Territory or Possession\n\
    \     \n \n \n \n \n    Other\n    \n \n \n     Independent School Districts\n\
    \     \n \n     Public Housing Authorities/Indian Housing Authorities\n     \n\
    \ \n     Native American Tribal Organizations (other than Federally recognized\
    \ tribal governments)\n     \n \n     Faith-based or Community-based Organizations\n\
    \     \n \n     Regional Organizations\n     \n \n \n \n   Foreign Organizations\n\
    \    \n \n \n    Non-domestic (non-U.S.) Entities (Foreign Organization)\n   \
    \  \n     are not\n     \n    eligible to apply.\n    \n \n \n \n    Non-domestic\
    \ (non-U.S.) components of U.S. Organizations\n     \n     are not\n     \n  \
    \  eligible to apply.\n    \n \n \n \n    Foreign components, as\n     \n    \
    \ defined in the NIH Grants Policy Statement\n     \n    ,\n     \n     are\n\
    \     \n    allowed.\n    \n \n \n   Required Registrations\n    \n \n     Applicant\
    \ organizations\n     \n \n \n    Applicant organizations must complete and maintain\
    \ the following registrations as described in the\n     \n     How to Apply- Application\
    \ Guide\n     \n    to be eligible to apply for or receive an award. All registrations\
    \ must be completed prior to the application being submitted. Registration can\
    \ take 6 weeks or more, so applicants should begin the registration process as\
    \ soon as possible. Failure to complete registrations in advance of a due date\
    \ is not a valid reason for a late submission, please reference\n     \n     NIH\
    \ Grants Policy Statement Section 2.3.9.2 Electronically Submitted Applications\n\
    \     \n    for additional information.\n    \n \n \n \n      System for Award\
    \ Management (SAM)\n      \n     – Applicants must complete and maintain an active\
    \ registration,\n      \n      which requires renewal at least annually\n    \
    \  \n     . The renewal process may require as much time as the initial registration.\
    \ SAM registration includes the assignment of a Commercial and Government Entity\
    \ (CAGE) Code for domestic organizations which have not already been assigned\
    \ a CAGE Code.\n      \n \n \n        NATO Commercial and Government Entity (NCAGE)\
    \ Code\n        \n       – Foreign organizations must obtain an NCAGE code (in\
    \ lieu of a CAGE code) in order to register in SAM.\n       \n \n       Unique\
    \ Entity Identifier (UEI) - A UEI is issued as part of the SAM.gov registration\
    \ process. The same UEI must be used for all registrations, as well as on the\
    \ grant application.\n       \n \n \n \n \n      eRA Commons\n      \n     - Once\
    \ the unique organization identifier is established, organizations can register\
    \ with eRA Commons in tandem with completing their Grants.gov registration; all\
    \ registrations must be in place by time of submission. eRA Commons requires organizations\
    \ to identify at least one Signing Official (SO) and at least one Program Director/Principal\
    \ Investigator (PD/PI) account in order to submit an application.\n     \n \n\
    \ \n      Grants.gov\n      \n     – Applicants must have an active SAM registration\
    \ in order to complete the Grants.gov registration.\n     \n \n \n \n     Program\
    \ Directors/Principal Investigators (PD(s)/PI(s))\n     \n \n \n    All PD(s)/PI(s)\
    \ must have an eRA Commons account.  PD(s)/PI(s) should work with their organizational\
    \ officials to either create a new account or to affiliate their existing account\
    \ with the applicant organization in eRA Commons. If the PD/PI is also the organizational\
    \ Signing Official, they must have two distinct eRA Commons accounts, one for\
    \ each role. Obtaining an eRA Commons account can take up to 2 weeks.\n    \n\
    \ \n \n   Eligible Individuals (Program Director/Principal Investigator)\n   \
    \ \n    Any individual(s) with the skills, knowledge, and resources necessary\
    \ to carry out the proposed research as the Program Director(s)/Principal Investigator(s)\
    \ (PD(s)/PI(s)) is invited to work with his/her organization to develop an application\
    \ for support.\n    \n \n    For institutions/organizations proposing multiple\
    \ PDs/PIs, visit the Multiple Program Director/Principal Investigator Policy and\
    \ submission details in the Senior/Key Person Profile (Expanded) Component of\
    \ the\n     \n     How to Apply - Application Guide\n     \n    .\n    \n \n \n\
    \ \n    An NIH intramural scientist may not serve as the PD/PI of an NCDDG but\
    \ may participate as a research collaborator or consultant (see\n     \n \n \n\
    \     Section IV.7\n     \n \n \n    for more information).\n    \n \n \n \n \
    \   2. Cost Sharing\n    \n \n    This NOFO does not require cost sharing as defined\
    \ in the\n     \n     NIH Grants Policy Statement\n     \n \n     Section 1.2-\
    \ Definitions of Terms.\n     \n \n \n \n \n    3. Additional Information on Eligibility\n\
    \    \n \n    Number of Applications\n    \n \n \n \n    Applicant organizations\
    \ may submit more than one application, provided that each application is scientifically\
    \ distinct.\n    \n \n    The NIH will not accept duplicate or highly overlapping\
    \ applications under review at the same time per\n     \n     NIH Grants Policy\
    \ Statement Section 2.3.7.4 Submission of Resubmission Application\n     \n  \
    \  . This means that the NIH will not accept:\n    \n \n \n     A new (A0) application\
    \ that is submitted before issuance of the summary statement from the review of\
    \ an overlapping new (A0) or resubmission (A1) application.\n     \n \n     A\
    \ resubmission (A1) application that is submitted before issuance of the summary\
    \ statement from the review of the previous new (A0) application.\n     \n \n\
    \     An application that has substantial overlap with another application pending\
    \ appeal of initial peer review (see\n      \n      NIH Grants Policy Statement\
    \ 2.3.9.4 Similar, Essentially Identical, or Identical Applications\n      \n\
    \     )."
- source_sentence: Can an organization submit multiple applications for the RFA-HL-26-011
    opportunity, and what conditions must be met for these applications?
  sentences:
  - "PAR-25-378: Intervention Research to Improve Native American Health (R34 Clinical\
    \ Trial Optional) Section VI. Award Administration Information\n    \n \n \n \n\
    \    1. Award Notices\n    \n \n    A Notice of Award (NoA) is the official authorizing\
    \ document notifying the applicant that an award has been made and that funds\
    \ may be requested from the designated HHS payment system or office. The NoA is\
    \ signed by the Grants Management Officer and emailed to the recipient’s business\
    \ official.\n    \n \n    In accepting the award, the recipient agrees that any\
    \ activities under the award are subject to all provisions currently in effect\
    \ or implemented during the period of the award, other Department regulations\
    \ and policies in effect at the time of the award, and applicable statutory provisions.\n\
    \    \n \n    Recipients must comply with any funding restrictions described in\n\
    \     \n     Section IV.6. Funding Restrictions\n     \n    . Any pre-award costs\
    \ incurred before receipt of the NoA are at the applicant's own risk. For more\
    \ information on the Notice of Award, please refer to the\n     \n     NIH Grants\
    \ Policy Statement Section 5. The Notice of Award\n     \n    and NIH Grants &\
    \ Funding website, see\n     \n     Award Process.\n     \n \n \n \n \n    Individual\
    \ awards are based on the application submitted to, and as approved by, the NIH\
    \ and are subject to the IC-specific terms and conditions identified in the NoA.\n\
    \    \n \n    ClinicalTrials.gov: If an award provides for one or more clinical\
    \ trials. By law (Title VIII, Section 801 of Public Law 110-85), the \"responsible\
    \ party\" must register and submit results information for certain “applicable\
    \ clinical trials” on the ClinicalTrials.gov Protocol Registration and Results\
    \ System Information Website (\n     \n     https://register.clinicaltrials.gov\n\
    \     \n    ). NIH expects registration and results reporting of all trials whether\
    \ required under the law or not. For more information, see\n     \n     https://grants.nih.gov/policy/clinical-trials/reporting/index.htm\n\
    \     \n \n \n    Institutional Review Board or Independent Ethics Committee Approval:\
    \ Recipient institutions must ensure that all protocols are reviewed by their\
    \ IRB or IEC. To help ensure the safety of participants enrolled in NIH-funded\
    \ studies, the recipient must provide NIH copies of documents related to all major\
    \ changes in the status of ongoing protocols.\n    \n \n    Data and Safety Monitoring\
    \ Requirements: The NIH policy for data and safety monitoring requires oversight\
    \ and monitoring of all NIH-conducted or -supported human biomedical and behavioral\
    \ intervention studies (clinical trials) to ensure the safety of participants\
    \ and the validity and integrity of the data. Further information concerning these\
    \ requirements is found at http://grants.nih.gov/grants/policy/hs/data_safety.htm\
    \ and in the application instructions (SF424 (R&R) and PHS 398).\n    \n \n  \
    \  Investigational New Drug or Investigational Device Exemption Requirements:\
    \ Consistent with federal regulations, clinical research projects involving the\
    \ use of investigational therapeutics, vaccines, or other medical interventions\
    \ (including licensed products and devices for a purpose other than that for which\
    \ they were licensed) in humans under a research protocol must be performed under\
    \ a Food and Drug Administration (FDA) investigational new drug (IND) or investigational\
    \ device exemption (IDE).\n    \n \n \n \n    2. Administrative and National Policy\
    \ Requirements\n    \n \n    The following Federal wide and HHS-specific policy\
    \ requirements apply to awards funded through NIH:\n    \n \n \n     The rules\
    \ listed at\n      \n      2 CFR Part 200\n      \n     , Uniform Administrative\
    \ Requirements, Cost Principles, and Audit Requirements for Federal Awards.\n\
    \     \n \n     All NIH grant and cooperative agreement awards include the\n \
    \     \n      NIH Grants Policy Statement\n      \n     as part of the terms and\
    \ conditions in the Notice of Award (NoA). The NoA includes the requirements of\
    \ this NOFO. For these terms of award, see the\n      \n      NIH Grants Policy\
    \ Statement Part II: Terms and Conditions of NIH Grant Awards, Subpart A: General\n\
    \      \n     and\n      \n      Part II: Terms and Conditions of NIH Grant Awards,\
    \ Subpart B: Terms and Conditions for Specific Types of Grants, Recipients, and\
    \ Activities\n      \n     .\n     \n \n     If a recipient receives an award,\
    \ the recipient must follow all applicable nondiscrimination laws. The recipient\
    \ agrees to this when registering in SAM.gov. The recipient must also submit an\
    \ Assurance of Compliance (\n      \n      HHS-690\n      \n     ). To learn more,\
    \ see the\n      \n      Laws and Regulations Enforced by the HHS Office for Civil\
    \ Rights website\n      \n     .\n      \n \n       HHS recognizes that NIH research\
    \ projects are often limited in scope for many reasons that are nondiscriminatory,\
    \ such as the principal investigator’s scientific interest, funding limitations,\
    \ recruitment requirements, and other considerations. Thus, criteria in research\
    \ protocols that target or exclude certain populations are warranted where nondiscriminatory\
    \ justifications establish that such criteria are appropriate with respect to\
    \ the health or safety of the subjects, the scientific study design, or the purpose\
    \ of the research. For additional guidance regarding how the provisions apply\
    \ to NIH grant programs, please contact the Scientific/Research Contact that is\
    \ identified in Section VII under Agency Contacts of this NOFO.\n       \n \n\
    \ \n \n \n    All federal statutes and regulations relevant to federal financial\
    \ assistance, including those highlighted in\n     \n     NIH Grants Policy Statement\
    \ Section 4 Public Policy Requirements, Objectives and Other Appropriation Mandates.\n\
    \     \n \n \n    Recipients are responsible for ensuring that their activities\
    \ comply with all applicable federal regulations.  NIH may terminate awards under\
    \ certain circumstances.  See\n     \n     2 CFR Part 200.340 Termination\n  \
    \   \n    and\n     \n     NIH Grants Policy Statement Section 8.5.2 Remedies\
    \ for Noncompliance or Enforcement Actions: Suspension, Termination, and Withholding\
    \ of Support\n     \n    .\n    \n \n    Successful recipients under this NOFO\
    \ agree that:\n    \n \n    Where the award funding involves implementing, acquiring,\
    \ or upgrading health IT for activities by any funded entity, recipients and subrecipient(s)\
    \ are required to: Use health IT that meets standards and implementation specifications\
    \ adopted in 45 CFR part 170, Subpart B, if such standards and implementation\
    \ specifications can support the activity.  Visit\n     \n     https://www.ecfr.gov/current/title-45/subtitle-A/subchapter-D/part-170/subpart-B\n\
    \     \n    to learn more.\n    \n \n    Where the award funding involves implementing,\
    \ acquiring, or upgrading health IT for activities by eligible clinicians in ambulatory\
    \ settings, or hospitals, eligible under Sections 4101, 4102, and 4201 of the\
    \ HITECH Act, use health IT certified under the ONC Health IT Certification Program\
    \ if certified technology can support the activity. Visit\n     \n     https://www.healthit.gov/topic/certification-ehrs/certification-health-it\n\
    \     \n    to learn more.\n    \n \n    Pursuant to the Cybersecurity Act of\
    \ 2015, Div. N, § 405, Pub. Law 114-113, 6 USC § 1533(d), the HHS Secretary has\
    \ established a common set of voluntary, consensus-based, and industry-led guidelines,\
    \ best practices, methodologies, procedures, and processes.\n    \n \n    Successful\
    \ recipients under this NOFO agree that:\n    \n \n    When recipients, subrecipients,\
    \ or third-party entities have:\n    \n \n    1) ongoing and consistent access\
    \ to HHS owned or operated information or operational technology systems; and\n\
    \    \n \n    2) receive, maintain, transmit, store, access, exchange, process,\
    \ or utilize personal identifiable information (PII) or personal health information\
    \ (PHI) obtained from the awarding HHS agency for the purposes of executing the\
    \ award.\n    \n \n    Recipients shall develop plans and procedures, modeled\
    \ after the\n     \n     NIST Cybersecurity framework\n     \n    , to protect\
    \ HHS systems and data. Please refer to\n     \n     NIH Post-Award Monitoring\
    \ and Reporting\n     \n    for additional information.\n    \n \n \n   Cooperative\
    \ Agreement Terms and Conditions of Award\n    \n    Not Applicable\n    \n \n\
    \ \n   3. Data Management and Sharing\n    \n    Consistent with the 2023 NIH\
    \ Policy for Data Management and Sharing, when data management and sharing is\
    \ applicable to the award, recipients will be required to adhere to the Data Management\
    \ and Sharing requirements as outlined in the\n     \n     NIH Grants Policy Statement\n\
    \     \n    . Upon the approval of a Data Management and Sharing Plan, it is required\
    \ for recipients to implement the plan as described.\n    \n \n \n \n    4. Reporting\n\
    \    \n \n    When multiple years are involved, recipients will be required to\
    \ submit the\n     \n     Research Performance Progress Report (RPPR)\n     \n\
    \    annually and financial statements as required in the\n     \n     NIH Grants\
    \ Policy Statement Section 8.4.1 Reporting.\n     \n    To learn more about post-award\
    \ monitoring and reporting, see the NIH Grants & Funding website, see\n     \n\
    \     Post-Award Monitoring and Reporting\n     \n    .\n    \n \n \n \n    A\
    \ final RPPR, invention statement, and the expenditure data portion of the Federal\
    \ Financial Report are required for closeout of an award, as described in the\n\
    \     \n     NIH Grants Policy Statement Section 8.6 Closeout\n     \n    . NIH\
    \ NOFOs outline intended research goals and objectives. Post award, NIH will review\
    \ and measure performance based on the details and outcomes that are shared within\
    \ the RPPR, as described at 2 CFR Part 200.301."
  - "PAR-25-378: Intervention Research to Improve Native American Health (R34 Clinical\
    \ Trial Optional) Section II. Award Information\n    \n \n \n   Funding Instrument\n\
    \    \n    Grant: A financial assistance mechanism providing money, property,\
    \ or both to an eligible entity to carry out an approved project or activity.\n\
    \    \n \n \n   Application Types Allowed\n   New\n    \n   Resubmission\n   \
    \ \n \n \n \n    The\n     \n     OER Glossary\n     \n    and the How to Apply\
    \ Application Guide provide details on these application types. Only those application\
    \ types listed here are allowed for this NOFO.\n    \n \n \n   Clinical Trial?\n\
    \    \n    Optional: Accepting applications that either propose or do not propose\
    \ clinical trial(s).\n    \n \n \n \n \n     Need help determining whether you\
    \ are doing a clinical trial?\n     \n \n \n \n   Funds Available and Anticipated\
    \ Number of Awards\n    \n    The number of awards is contingent upon NIH appropriations\
    \ and the submission of a sufficient number of meritorious applications.\n   \
    \ \n \n \n   Award Budget\n    \n    Applicants may request direct costs of up\
    \ to $450,000 for three years. Although variations from year to year are permissible,\
    \ in no case may any year be more than $225,000 in direct costs, and total direct\
    \ costs for the entire project period may not exceed $450,000.\n    \n \n \n \
    \  Award Project Period\n    \n    The scope of the proposed project should determine\
    \ the project period. The maximum project period is 3 years.\n    \n This variable\
    \ defines that we need to start a new row.  \n \n \n \n    NIH grants policies\
    \ as described in the\n     \n     NIH Grants Policy Statement\n     \n    will\
    \ apply to the applications submitted and awards made from this NOFO."
  - "RFA-HL-26-011: Leadership and Coordination Center (LACC) for the MACS/WIHS Combined\
    \ Cohort Study (MWCCS) (U01 Clinical Trials Not Allowed) Section III. Eligibility\
    \ Information\n    \n \n \n \n    1. Eligible Applicants\n    \n \n \n   Eligible\
    \ Organizations\n    \n    Higher Education Institutions\n    \n \n \n     Public/State\
    \ Controlled Institutions of Higher Education\n     \n \n     Private Institutions\
    \ of Higher Education\n     \n \n \n    The following types of Higher Education\
    \ Institutions are always encouraged to apply for NIH support as Public or Private\
    \ Institutions of Higher Education:\n    \n \n \n     Hispanic-serving Institutions\n\
    \     \n \n     Historically Black Colleges and Universities (HBCUs)\n     \n\
    \ \n     Tribally Controlled Colleges and Universities (TCCUs)\n     \n \n   \
    \  Alaska Native and Native Hawaiian Serving Institutions\n     \n \n     Asian\
    \ American Native American Pacific Islander Serving Institutions (AANAPISIs)\n\
    \     \n \n \n    Nonprofits Other Than Institutions of Higher Education\n   \
    \ \n \n \n     Nonprofits with 501(c)(3) IRS Status (Other than Institutions of\
    \ Higher Education)\n     \n \n     Nonprofits without 501(c)(3) IRS Status (Other\
    \ than Institutions of Higher Education)\n     \n \n \n    For-Profit Organizations\n\
    \    \n \n \n     Small Businesses\n     \n \n     For-Profit Organizations (Other\
    \ than Small Businesses)\n     \n \n \n    Local Governments\n    \n \n \n   \
    \  State Governments\n     \n \n     County Governments\n     \n \n     City or\
    \ Township Governments\n     \n \n     Special District Governments\n     \n \n\
    \     Indian/Native American Tribal Governments (Federally Recognized)\n     \n\
    \ \n     Indian/Native American Tribal Governments (Other than Federally Recognized).\n\
    \     \n \n \n \n \n    Federal Governments\n    \n \n \n     Eligible Agencies\
    \ of the Federal Government\n     \n \n     U.S. Territory or Possession\n   \
    \  \n \n \n \n \n    Other\n    \n \n \n     Independent School Districts\n  \
    \   \n \n     Public Housing Authorities/Indian Housing Authorities\n     \n \n\
    \     Native American Tribal Organizations (other than Federally recognized tribal\
    \ governments)\n     \n \n     Faith-based or Community-based Organizations\n\
    \     \n \n     Regional Organizations\n     \n \n \n \n   Foreign Organizations\n\
    \    \n \n \n    Non-domestic (non-U.S.) Entities (Foreign Organizations)\n  \
    \   \n     are not\n     \n    eligible to apply.\n    \n \n \n \n    Non-domestic\
    \ (non-U.S.) components of U.S. Organizations\n     \n     are not\n     \n  \
    \  eligible to apply.\n    \n \n \n \n    Foreign components, as\n     \n    \
    \ defined in the NIH Grants Policy Statement\n     \n    ,\n     \n     are not\n\
    \     \n    allowed.\n    \n \n \n   Required Registrations\n    \n \n     Applicant\
    \ Organizations\n     \n \n \n    Applicant organizations must complete and maintain\
    \ the following registrations as described in the How to Apply- Application Guide\
    \ to be eligible to apply for or receive an award. All registrations must be completed\
    \ prior to the application being submitted. Registration can take 6 weeks or more,\
    \ so applicants should begin the registration process as soon as possible. Failure\
    \ to complete registrations in advance of a due date is not a valid reason for\
    \ a late submission, please reference the\n     \n     NIH Grants Policy Statement\
    \ Section 2.3.9.2 Electronically Submitted Applications\n     \n    for additional\
    \ information.\n    \n \n \n \n      System for Award Management (SAM) –\n   \
    \   \n     Applicants must complete and maintain an active registration,\n   \
    \   \n      which requires renewal at least annually\n      \n     . The renewal\
    \ process may require as much time as the initial registration. SAM registration\
    \ includes the assignment of a Commercial and Government Entity (CAGE) Code for\
    \ domestic organizations which have not already been assigned a CAGE Code.\n \
    \     \n \n \n        NATO Commercial and Government Entity (NCAGE) Code\n   \
    \     \n       – Foreign organizations must obtain an NCAGE code (in lieu of a\
    \ CAGE code) in order to register in SAM.\n       \n \n       Unique Entity Identifier\
    \ (UEI) - A UEI is issued as part of the SAM.gov registration process. The same\
    \ UEI must be used for all registrations, as well as on the grant application.\n\
    \       \n \n \n \n \n      eRA Commons\n      \n     - Once the unique organization\
    \ identifier is established, organizations can register with eRA Commons in tandem\
    \ with completing their Grants.gov registrations; all registrations must be in\
    \ place by time of submission. eRA Commons requires organizations to identify\
    \ at least one Signing Official (SO) and at least one Program Director/Principal\
    \ Investigator (PD/PI) account in order to submit an application.\n     \n \n\
    \ \n      Grants.gov\n      \n     – Applicants must have an active SAM registration\
    \ in order to complete the Grants.gov registration.\n     \n \n \n \n     Program\
    \ Directors/Principal Investigators (PD(s)/PI(s))\n     \n \n \n    All PD(s)/PI(s)\
    \ must have an eRA Commons account.  PD(s)/PI(s) should work with their organizational\
    \ officials to either create a new account or to affiliate their existing account\
    \ with the applicant organization in eRA Commons. If the PD/PI is also the organizational\
    \ Signing Official, they must have two distinct eRA Commons accounts, one for\
    \ each role. Obtaining an eRA Commons account can take up to 2 weeks.\n    \n\
    \ \n \n   Eligible Individuals (Program Director/Principal Investigator)\n   \
    \ \n    Any individual(s) with the skills, knowledge, and resources necessary\
    \ to carry out the proposed research as the Program Director(s)/Principal Investigator(s)\
    \ (PD(s)/PI(s)) is invited to work with their organization to develop an application\
    \ for support.\n    \n \n    For institutions/organizations proposing multiple\
    \ PDs/PIs, visit the Multiple Program Director/Principal Investigator Policy and\
    \ submission details in the Senior/Key Person Profile (Expanded) Component of\
    \ the How to Apply-Application Guide.\n    \n \n \n \n    A multiple PI (mPI)\
    \ leadership structure is required. The LACC mPI team should include individuals\
    \ with demonstrated deep knowledge of, and familiarity with, the MWCCS. In addition,\
    \ the team should include at least one clinician with experience in clinical care\
    \ of patients living with HIV and/or relevant comorbidities, as well as one or\
    \ more individuals with epidemiologic cohort study leadership experience.Individuals\
    \ may not apply to be an mPI of both the LACC and Data Analysis and Sharing Center\
    \ (DASC) (\n     \n     RFA-HL-26-010\n     \n    ). Applications without an mPI\
    \ leadership structure will be considered incomplete and will not proceed to peer\
    \ review.\n    \n \n \n \n    2. Cost Sharing\n    \n \n    This NOFO does not\
    \ require cost sharing as defined in the\n     \n     NIH Grants Policy Statement\
    \ Section 1.2 Definition of Terms\n     \n    .\n    \n \n \n \n    3. Additional\
    \ Information on Eligibility\n    \n \n    Number of Applications\n    \n \n \n\
    \ \n    Applicant organizations may submit more than one application, provided\
    \ that each application is scientifically distinct.\n    \n \n    The NIH will\
    \ not accept duplicate or highly overlapping applications under review at the\
    \ same time, per\n     \n     NIH Grants Policy Statement Section 2.3.7.4 Submission\
    \ of Resubmission Application\n     \n    . This means that the NIH will not accept:\n\
    \    \n \n \n     A new (A0) application that is submitted before issuance of\
    \ the summary statement from the review of an overlapping new (A0) or resubmission\
    \ (A1) application.\n     \n \n     A resubmission (A1) application that is submitted\
    \ before issuance of the summary statement from the review of the previous new\
    \ (A0) application.\n     \n \n     An application that has substantial overlap\
    \ with another application pending appeal of initial peer review (see\n      \n\
    \      NIH Grants Policy Statement 2.3.9.4 Similar, Essentially Identical, or\
    \ Identical Applications\n      \n     )."
- source_sentence: What is the purpose of the funding opportunity RFA-DK-26-007 titled
    "Collaborative Research Using Biosamples and/or Data from Type 1 Diabetes Clinical
    Studies"?
  sentences:
  - Department of Health and Human Services
  - "RFA-DK-26-007: Collaborative Research Using Biosamples and/or Data from Type\
    \ 1 Diabetes Clinical Studies (R01 - Clinical Trial Not Allowed) Part 1. Overview\
    \ Information\n    \n \n \n   Participating Organization(s)\n    \n    National\
    \ Institutes of Health (\n     \n     NIH\n     \n    )\n    \n \n \n   Components\
    \ of Participating Organizations\n    \n    National Institute of Diabetes and\
    \ Digestive and Kidney Diseases (\n     \n     NIDDK\n     \n    )\n     \n \n\
    \     Office of The Director, National Institutes of Health (\n      \n      OD\n\
    \      \n     )\n     \n \n \n   Funding Opportunity Title\n    \n    Collaborative\
    \ Research Using Biosamples and/or Data from Type 1 Diabetes Clinical Studies\
    \ (R01 - Clinical Trial Not Allowed)\n    \n \n \n   Activity Code\n    \n \n\
    \     R01\n     \n    Research Project Grant\n    \n \n \n   Announcement Type\n\
    \   Reissue of\n    \n    RFA-DK-22-021\n    \n \n \n \n   Related Notices\n \
    \   \n \n \n      April 4, 2024\n      \n     - Overview of Grant Application\
    \ and Review Changes for Due Dates on or after January 25, 2025. See Notice\n\
    \      \n      NOT-OD-24-084\n      \n     .\n     \n \n \n      August 31, 2022\n\
    \      \n     - Implementation Changes for Genomic Data Sharing Plans Included\
    \ with Applications Due on or after January 25, 2023. See Notice\n      \n   \
    \   NOT-OD-22-198\n      \n     .\n     \n \n \n      August 5, 2022\n      \n\
    \     - Implementation Details for the NIH Data Management and Sharing Policy.\
    \ See Notice\n      \n      NOT-OD-22-189\n      \n     .\n     \n \n \n \n  \
    \ Funding Opportunity Number (FON)\n    \n    RFA-DK-26-007\n    \n \n \n   Companion\
    \ Funding Opportunity\n   None\n    \n \n   Number of Applications\n    \n   \
    \ See\n     \n     Section III. 3. Additional Information on Eligibility\n   \
    \  \n    .\n    \n \n \n   Assistance Listing Number(s)\n   93.847\n    \n \n\
    \   Funding Opportunity Purpose\n    \n    This Notice of Funding Opportunity\
    \ (NOFO) invites applications for studies of type 1 diabetes etiology and pathogenesis\
    \ using data and samples from clinical trials and studies. This opportunity is\
    \ intended to fund investigative teams collaborating to answer important questions\
    \ about disease mechanisms leading to improved delay and durable prevention of\
    \ type 1 diabetes. This NOFO is associated with the Special Diabetes Program (\n\
    \     \n     https://www.niddk.nih.gov/about-niddk/research-areas/diabetes/type-1-diabetes-special-statutory-funding-program/about-special-diabetes-program\n\
    \     \n    ) which funds research on the prevention, treatment, and cure of type\
    \ 1 diabetes and its complications, including unique, innovative, and collaborative\
    \ research consortia and clinical trials networks.\n    \n \n \n \n \n \n \n \
    \  Funding Opportunity Goal(s)\n    \n    To promote extramural basic and clinical\
    \ biomedical research that improves the understanding of the mechanisms underlying\
    \ disease and leads to improved preventions, diagnosis, and treatment of diabetes,\
    \ digestive, and kidney diseases. Programmatic areas within the National Institute\
    \ of Diabetes and Digestive and Kidney Diseases include diabetes, digestive, endocrine,\
    \ hematologic, liver, metabolic, nephrologic, nutrition, obesity, and urologic\
    \ diseases.\n    \n This variable defines that we need to start a new row."
  - "RFA-DK-26-007: Collaborative Research Using Biosamples and/or Data from Type\
    \ 1 Diabetes Clinical Studies (R01 - Clinical Trial Not Allowed) Part 1. Overview\
    \ Information\n    \n \n \n   Participating Organization(s)\n    \n    National\
    \ Institutes of Health (\n     \n     NIH\n     \n    )\n    \n \n \n   Components\
    \ of Participating Organizations\n    \n    National Institute of Diabetes and\
    \ Digestive and Kidney Diseases (\n     \n     NIDDK\n     \n    )\n     \n \n\
    \     Office of The Director, National Institutes of Health (\n      \n      OD\n\
    \      \n     )\n     \n \n \n   Funding Opportunity Title\n    \n    Collaborative\
    \ Research Using Biosamples and/or Data from Type 1 Diabetes Clinical Studies\
    \ (R01 - Clinical Trial Not Allowed)\n    \n \n \n   Activity Code\n    \n \n\
    \     R01\n     \n    Research Project Grant\n    \n \n \n   Announcement Type\n\
    \   Reissue of\n    \n    RFA-DK-22-021\n    \n \n \n \n   Related Notices\n \
    \   \n \n \n      April 4, 2024\n      \n     - Overview of Grant Application\
    \ and Review Changes for Due Dates on or after January 25, 2025. See Notice\n\
    \      \n      NOT-OD-24-084\n      \n     .\n     \n \n \n      August 31, 2022\n\
    \      \n     - Implementation Changes for Genomic Data Sharing Plans Included\
    \ with Applications Due on or after January 25, 2023. See Notice\n      \n   \
    \   NOT-OD-22-198\n      \n     .\n     \n \n \n      August 5, 2022\n      \n\
    \     - Implementation Details for the NIH Data Management and Sharing Policy.\
    \ See Notice\n      \n      NOT-OD-22-189\n      \n     .\n     \n \n \n \n  \
    \ Funding Opportunity Number (FON)\n    \n    RFA-DK-26-007\n    \n \n \n   Companion\
    \ Funding Opportunity\n   None\n    \n \n   Number of Applications\n    \n   \
    \ See\n     \n     Section III. 3. Additional Information on Eligibility\n   \
    \  \n    .\n    \n \n \n   Assistance Listing Number(s)\n   93.847\n    \n \n\
    \   Funding Opportunity Purpose\n    \n    This Notice of Funding Opportunity\
    \ (NOFO) invites applications for studies of type 1 diabetes etiology and pathogenesis\
    \ using data and samples from clinical trials and studies. This opportunity is\
    \ intended to fund investigative teams collaborating to answer important questions\
    \ about disease mechanisms leading to improved delay and durable prevention of\
    \ type 1 diabetes. This NOFO is associated with the Special Diabetes Program (\n\
    \     \n     https://www.niddk.nih.gov/about-niddk/research-areas/diabetes/type-1-diabetes-special-statutory-funding-program/about-special-diabetes-program\n\
    \     \n    ) which funds research on the prevention, treatment, and cure of type\
    \ 1 diabetes and its complications, including unique, innovative, and collaborative\
    \ research consortia and clinical trials networks.\n    \n \n \n \n \n \n \n \
    \  Funding Opportunity Goal(s)\n    \n    To promote extramural basic and clinical\
    \ biomedical research that improves the understanding of the mechanisms underlying\
    \ disease and leads to improved preventions, diagnosis, and treatment of diabetes,\
    \ digestive, and kidney diseases. Programmatic areas within the National Institute\
    \ of Diabetes and Digestive and Kidney Diseases include diabetes, digestive, endocrine,\
    \ hematologic, liver, metabolic, nephrologic, nutrition, obesity, and urologic\
    \ diseases.\n    \n This variable defines that we need to start a new row."
pipeline_tag: sentence-similarity
library_name: sentence-transformers
metrics:
- cosine_accuracy@1
- cosine_accuracy@3
- cosine_accuracy@5
- cosine_accuracy@10
- cosine_precision@1
- cosine_precision@3
- cosine_precision@5
- cosine_precision@10
- cosine_recall@1
- cosine_recall@3
- cosine_recall@5
- cosine_recall@10
- cosine_ndcg@10
- cosine_mrr@10
- cosine_map@100
model-index:
- name: SentenceTransformer based on Snowflake/snowflake-arctic-embed-l
  results:
  - task:
      type: information-retrieval
      name: Information Retrieval
    dataset:
      name: Unknown
      type: unknown
    metrics:
    - type: cosine_accuracy@1
      value: 0.875
      name: Cosine Accuracy@1
    - type: cosine_accuracy@3
      value: 1.0
      name: Cosine Accuracy@3
    - type: cosine_accuracy@5
      value: 1.0
      name: Cosine Accuracy@5
    - type: cosine_accuracy@10
      value: 1.0
      name: Cosine Accuracy@10
    - type: cosine_precision@1
      value: 0.875
      name: Cosine Precision@1
    - type: cosine_precision@3
      value: 0.3333333333333333
      name: Cosine Precision@3
    - type: cosine_precision@5
      value: 0.20000000000000004
      name: Cosine Precision@5
    - type: cosine_precision@10
      value: 0.10000000000000002
      name: Cosine Precision@10
    - type: cosine_recall@1
      value: 0.875
      name: Cosine Recall@1
    - type: cosine_recall@3
      value: 1.0
      name: Cosine Recall@3
    - type: cosine_recall@5
      value: 1.0
      name: Cosine Recall@5
    - type: cosine_recall@10
      value: 1.0
      name: Cosine Recall@10
    - type: cosine_ndcg@10
      value: 0.9484108127976215
      name: Cosine Ndcg@10
    - type: cosine_mrr@10
      value: 0.9305555555555555
      name: Cosine Mrr@10
    - type: cosine_map@100
      value: 0.9305555555555555
      name: Cosine Map@100
---

# SentenceTransformer based on Snowflake/snowflake-arctic-embed-l

This is a [sentence-transformers](https://www.SBERT.net) model finetuned from [Snowflake/snowflake-arctic-embed-l](https://huggingface.co/Snowflake/snowflake-arctic-embed-l). It maps sentences & paragraphs to a 1024-dimensional dense vector space and can be used for semantic textual similarity, semantic search, paraphrase mining, text classification, clustering, and more.

## Model Details

### Model Description
- **Model Type:** Sentence Transformer
- **Base model:** [Snowflake/snowflake-arctic-embed-l](https://huggingface.co/Snowflake/snowflake-arctic-embed-l) <!-- at revision d8fb21ca8d905d2832ee8b96c894d3298964346b -->
- **Maximum Sequence Length:** 512 tokens
- **Output Dimensionality:** 1024 dimensions
- **Similarity Function:** Cosine Similarity
<!-- - **Training Dataset:** Unknown -->
<!-- - **Language:** Unknown -->
<!-- - **License:** Unknown -->

### Model Sources

- **Documentation:** [Sentence Transformers Documentation](https://sbert.net)
- **Repository:** [Sentence Transformers on GitHub](https://github.com/UKPLab/sentence-transformers)
- **Hugging Face:** [Sentence Transformers on Hugging Face](https://huggingface.co/models?library=sentence-transformers)

### Full Model Architecture

```
SentenceTransformer(
  (0): Transformer({'max_seq_length': 512, 'do_lower_case': False}) with Transformer model: BertModel 
  (1): Pooling({'word_embedding_dimension': 1024, 'pooling_mode_cls_token': True, 'pooling_mode_mean_tokens': False, 'pooling_mode_max_tokens': False, 'pooling_mode_mean_sqrt_len_tokens': False, 'pooling_mode_weightedmean_tokens': False, 'pooling_mode_lasttoken': False, 'include_prompt': True})
  (2): Normalize()
)
```

## Usage

### Direct Usage (Sentence Transformers)

First install the Sentence Transformers library:

```bash
pip install -U sentence-transformers
```

Then you can load this model and run inference.
```python
from sentence_transformers import SentenceTransformer

# Download from the 🤗 Hub
model = SentenceTransformer("christinemahler/aie5-midter-new")
# Run inference
sentences = [
    'What is the purpose of the funding opportunity RFA-DK-26-007 titled "Collaborative Research Using Biosamples and/or Data from Type 1 Diabetes Clinical Studies"?',
    'RFA-DK-26-007: Collaborative Research Using Biosamples and/or Data from Type 1 Diabetes Clinical Studies (R01 - Clinical Trial Not Allowed) Part 1. Overview Information\n    \n \n \n   Participating Organization(s)\n    \n    National Institutes of Health (\n     \n     NIH\n     \n    )\n    \n \n \n   Components of Participating Organizations\n    \n    National Institute of Diabetes and Digestive and Kidney Diseases (\n     \n     NIDDK\n     \n    )\n     \n \n     Office of The Director, National Institutes of Health (\n      \n      OD\n      \n     )\n     \n \n \n   Funding Opportunity Title\n    \n    Collaborative Research Using Biosamples and/or Data from Type 1 Diabetes Clinical Studies (R01 - Clinical Trial Not Allowed)\n    \n \n \n   Activity Code\n    \n \n     R01\n     \n    Research Project Grant\n    \n \n \n   Announcement Type\n   Reissue of\n    \n    RFA-DK-22-021\n    \n \n \n \n   Related Notices\n    \n \n \n      April 4, 2024\n      \n     - Overview of Grant Application and Review Changes for Due Dates on or after January 25, 2025. See Notice\n      \n      NOT-OD-24-084\n      \n     .\n     \n \n \n      August 31, 2022\n      \n     - Implementation Changes for Genomic Data Sharing Plans Included with Applications Due on or after January 25, 2023. See Notice\n      \n      NOT-OD-22-198\n      \n     .\n     \n \n \n      August 5, 2022\n      \n     - Implementation Details for the NIH Data Management and Sharing Policy. See Notice\n      \n      NOT-OD-22-189\n      \n     .\n     \n \n \n \n   Funding Opportunity Number (FON)\n    \n    RFA-DK-26-007\n    \n \n \n   Companion Funding Opportunity\n   None\n    \n \n   Number of Applications\n    \n    See\n     \n     Section III. 3. Additional Information on Eligibility\n     \n    .\n    \n \n \n   Assistance Listing Number(s)\n   93.847\n    \n \n   Funding Opportunity Purpose\n    \n    This Notice of Funding Opportunity (NOFO) invites applications for studies of type 1 diabetes etiology and pathogenesis using data and samples from clinical trials and studies. This opportunity is intended to fund investigative teams collaborating to answer important questions about disease mechanisms leading to improved delay and durable prevention of type 1 diabetes. This NOFO is associated with the Special Diabetes Program (\n     \n     https://www.niddk.nih.gov/about-niddk/research-areas/diabetes/type-1-diabetes-special-statutory-funding-program/about-special-diabetes-program\n     \n    ) which funds research on the prevention, treatment, and cure of type 1 diabetes and its complications, including unique, innovative, and collaborative research consortia and clinical trials networks.\n    \n \n \n \n \n \n \n   Funding Opportunity Goal(s)\n    \n    To promote extramural basic and clinical biomedical research that improves the understanding of the mechanisms underlying disease and leads to improved preventions, diagnosis, and treatment of diabetes, digestive, and kidney diseases. Programmatic areas within the National Institute of Diabetes and Digestive and Kidney Diseases include diabetes, digestive, endocrine, hematologic, liver, metabolic, nephrologic, nutrition, obesity, and urologic diseases.\n    \n This variable defines that we need to start a new row.',
    'RFA-DK-26-007: Collaborative Research Using Biosamples and/or Data from Type 1 Diabetes Clinical Studies (R01 - Clinical Trial Not Allowed) Part 1. Overview Information\n    \n \n \n   Participating Organization(s)\n    \n    National Institutes of Health (\n     \n     NIH\n     \n    )\n    \n \n \n   Components of Participating Organizations\n    \n    National Institute of Diabetes and Digestive and Kidney Diseases (\n     \n     NIDDK\n     \n    )\n     \n \n     Office of The Director, National Institutes of Health (\n      \n      OD\n      \n     )\n     \n \n \n   Funding Opportunity Title\n    \n    Collaborative Research Using Biosamples and/or Data from Type 1 Diabetes Clinical Studies (R01 - Clinical Trial Not Allowed)\n    \n \n \n   Activity Code\n    \n \n     R01\n     \n    Research Project Grant\n    \n \n \n   Announcement Type\n   Reissue of\n    \n    RFA-DK-22-021\n    \n \n \n \n   Related Notices\n    \n \n \n      April 4, 2024\n      \n     - Overview of Grant Application and Review Changes for Due Dates on or after January 25, 2025. See Notice\n      \n      NOT-OD-24-084\n      \n     .\n     \n \n \n      August 31, 2022\n      \n     - Implementation Changes for Genomic Data Sharing Plans Included with Applications Due on or after January 25, 2023. See Notice\n      \n      NOT-OD-22-198\n      \n     .\n     \n \n \n      August 5, 2022\n      \n     - Implementation Details for the NIH Data Management and Sharing Policy. See Notice\n      \n      NOT-OD-22-189\n      \n     .\n     \n \n \n \n   Funding Opportunity Number (FON)\n    \n    RFA-DK-26-007\n    \n \n \n   Companion Funding Opportunity\n   None\n    \n \n   Number of Applications\n    \n    See\n     \n     Section III. 3. Additional Information on Eligibility\n     \n    .\n    \n \n \n   Assistance Listing Number(s)\n   93.847\n    \n \n   Funding Opportunity Purpose\n    \n    This Notice of Funding Opportunity (NOFO) invites applications for studies of type 1 diabetes etiology and pathogenesis using data and samples from clinical trials and studies. This opportunity is intended to fund investigative teams collaborating to answer important questions about disease mechanisms leading to improved delay and durable prevention of type 1 diabetes. This NOFO is associated with the Special Diabetes Program (\n     \n     https://www.niddk.nih.gov/about-niddk/research-areas/diabetes/type-1-diabetes-special-statutory-funding-program/about-special-diabetes-program\n     \n    ) which funds research on the prevention, treatment, and cure of type 1 diabetes and its complications, including unique, innovative, and collaborative research consortia and clinical trials networks.\n    \n \n \n \n \n \n \n   Funding Opportunity Goal(s)\n    \n    To promote extramural basic and clinical biomedical research that improves the understanding of the mechanisms underlying disease and leads to improved preventions, diagnosis, and treatment of diabetes, digestive, and kidney diseases. Programmatic areas within the National Institute of Diabetes and Digestive and Kidney Diseases include diabetes, digestive, endocrine, hematologic, liver, metabolic, nephrologic, nutrition, obesity, and urologic diseases.\n    \n This variable defines that we need to start a new row.',
]
embeddings = model.encode(sentences)
print(embeddings.shape)
# [3, 1024]

# Get the similarity scores for the embeddings
similarities = model.similarity(embeddings, embeddings)
print(similarities.shape)
# [3, 3]
```

<!--
### Direct Usage (Transformers)

<details><summary>Click to see the direct usage in Transformers</summary>

</details>
-->

<!--
### Downstream Usage (Sentence Transformers)

You can finetune this model on your own dataset.

<details><summary>Click to expand</summary>

</details>
-->

<!--
### Out-of-Scope Use

*List how the model may foreseeably be misused and address what users ought not to do with the model.*
-->

## Evaluation

### Metrics

#### Information Retrieval

* Evaluated with [<code>InformationRetrievalEvaluator</code>](https://sbert.net/docs/package_reference/sentence_transformer/evaluation.html#sentence_transformers.evaluation.InformationRetrievalEvaluator)

| Metric              | Value      |
|:--------------------|:-----------|
| cosine_accuracy@1   | 0.875      |
| cosine_accuracy@3   | 1.0        |
| cosine_accuracy@5   | 1.0        |
| cosine_accuracy@10  | 1.0        |
| cosine_precision@1  | 0.875      |
| cosine_precision@3  | 0.3333     |
| cosine_precision@5  | 0.2        |
| cosine_precision@10 | 0.1        |
| cosine_recall@1     | 0.875      |
| cosine_recall@3     | 1.0        |
| cosine_recall@5     | 1.0        |
| cosine_recall@10    | 1.0        |
| **cosine_ndcg@10**  | **0.9484** |
| cosine_mrr@10       | 0.9306     |
| cosine_map@100      | 0.9306     |

<!--
## Bias, Risks and Limitations

*What are the known or foreseeable issues stemming from this model? You could also flag here known failure cases or weaknesses of the model.*
-->

<!--
### Recommendations

*What are recommendations with respect to the foreseeable issues? For example, filtering explicit content.*
-->

## Training Details

### Training Dataset

#### Unnamed Dataset


* Size: 216 training samples
* Columns: <code>sentence_0</code> and <code>sentence_1</code>
* Approximate statistics based on the first 216 samples:
  |         | sentence_0                                                                        | sentence_1                                                                          |
  |:--------|:----------------------------------------------------------------------------------|:------------------------------------------------------------------------------------|
  | type    | string                                                                            | string                                                                              |
  | details | <ul><li>min: 19 tokens</li><li>mean: 34.9 tokens</li><li>max: 59 tokens</li></ul> | <ul><li>min: 8 tokens</li><li>mean: 377.44 tokens</li><li>max: 512 tokens</li></ul> |
* Samples:
  | sentence_0                                                                                                                                                | sentence_1                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |
  |:----------------------------------------------------------------------------------------------------------------------------------------------------------|:------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
  | <code>What initiatives is the Department of Health and Human Services pursuing under opportunity ID [insert ID] to improve public health outcomes?</code> | <code>Department of Health and Human Services</code>                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
  | <code>How does the title of opportunity ID [insert ID] align with the strategic goals of the Department of Health and Human Services?</code>              | <code>Department of Health and Human Services</code>                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
  | <code>What are the main goals of the funding opportunity titled "Laboratory Flexible Funding Model (LFFM)" under opportunity ID RFA-FD-25-007?</code>     | <code>RFA-FD-25-007: Laboratory Flexible Funding Model (LFFM) Part 1. Overview Information<br>    <br> <br> <br>   Participating Organization(s)<br>    <br>    U.S. Food and Drug Administration (<br>     <br>     FDA<br>     <br>    )<br>    <br> <br> <br> <br>    NOTE: The policies, guidelines, terms, and conditions stated in this Notice of Funding Opportunity (NOFO) may differ from those used by the NIH.  Where this NOFO provides specific written guidance that may differ from the general guidance provided in the grant application form, please follow the instructions given in this NOFO.<br>    <br> <br>    The FDA does not follow the NIH Page Limitation Guidelines or the NIH Review Criteria. Applicants are encouraged to consult with FDA Agency Contacts for additional information regarding page limits and the FDA Objective Review Process.<br>    <br> <br> <br>   Components of Participating Organizations<br>    <br>    FOOD AND DRUG ADMINISTRATION (<br>     <br>     FDA<br>     <br>    )<br>    <br> <br> <br>   Funding Opportunity Title<br>    <br>    Laboratory Flexible Funding Model (LFFM)<br>...</code> |
* Loss: [<code>MatryoshkaLoss</code>](https://sbert.net/docs/package_reference/sentence_transformer/losses.html#matryoshkaloss) with these parameters:
  ```json
  {
      "loss": "MultipleNegativesRankingLoss",
      "matryoshka_dims": [
          768,
          512,
          256,
          128,
          64
      ],
      "matryoshka_weights": [
          1,
          1,
          1,
          1,
          1
      ],
      "n_dims_per_step": -1
  }
  ```

### Training Hyperparameters
#### Non-Default Hyperparameters

- `eval_strategy`: steps
- `per_device_train_batch_size`: 10
- `per_device_eval_batch_size`: 10
- `num_train_epochs`: 10
- `multi_dataset_batch_sampler`: round_robin

#### All Hyperparameters
<details><summary>Click to expand</summary>

- `overwrite_output_dir`: False
- `do_predict`: False
- `eval_strategy`: steps
- `prediction_loss_only`: True
- `per_device_train_batch_size`: 10
- `per_device_eval_batch_size`: 10
- `per_gpu_train_batch_size`: None
- `per_gpu_eval_batch_size`: None
- `gradient_accumulation_steps`: 1
- `eval_accumulation_steps`: None
- `torch_empty_cache_steps`: None
- `learning_rate`: 5e-05
- `weight_decay`: 0.0
- `adam_beta1`: 0.9
- `adam_beta2`: 0.999
- `adam_epsilon`: 1e-08
- `max_grad_norm`: 1
- `num_train_epochs`: 10
- `max_steps`: -1
- `lr_scheduler_type`: linear
- `lr_scheduler_kwargs`: {}
- `warmup_ratio`: 0.0
- `warmup_steps`: 0
- `log_level`: passive
- `log_level_replica`: warning
- `log_on_each_node`: True
- `logging_nan_inf_filter`: True
- `save_safetensors`: True
- `save_on_each_node`: False
- `save_only_model`: False
- `restore_callback_states_from_checkpoint`: False
- `no_cuda`: False
- `use_cpu`: False
- `use_mps_device`: False
- `seed`: 42
- `data_seed`: None
- `jit_mode_eval`: False
- `use_ipex`: False
- `bf16`: False
- `fp16`: False
- `fp16_opt_level`: O1
- `half_precision_backend`: auto
- `bf16_full_eval`: False
- `fp16_full_eval`: False
- `tf32`: None
- `local_rank`: 0
- `ddp_backend`: None
- `tpu_num_cores`: None
- `tpu_metrics_debug`: False
- `debug`: []
- `dataloader_drop_last`: False
- `dataloader_num_workers`: 0
- `dataloader_prefetch_factor`: None
- `past_index`: -1
- `disable_tqdm`: False
- `remove_unused_columns`: True
- `label_names`: None
- `load_best_model_at_end`: False
- `ignore_data_skip`: False
- `fsdp`: []
- `fsdp_min_num_params`: 0
- `fsdp_config`: {'min_num_params': 0, 'xla': False, 'xla_fsdp_v2': False, 'xla_fsdp_grad_ckpt': False}
- `fsdp_transformer_layer_cls_to_wrap`: None
- `accelerator_config`: {'split_batches': False, 'dispatch_batches': None, 'even_batches': True, 'use_seedable_sampler': True, 'non_blocking': False, 'gradient_accumulation_kwargs': None}
- `deepspeed`: None
- `label_smoothing_factor`: 0.0
- `optim`: adamw_torch
- `optim_args`: None
- `adafactor`: False
- `group_by_length`: False
- `length_column_name`: length
- `ddp_find_unused_parameters`: None
- `ddp_bucket_cap_mb`: None
- `ddp_broadcast_buffers`: False
- `dataloader_pin_memory`: True
- `dataloader_persistent_workers`: False
- `skip_memory_metrics`: True
- `use_legacy_prediction_loop`: False
- `push_to_hub`: False
- `resume_from_checkpoint`: None
- `hub_model_id`: None
- `hub_strategy`: every_save
- `hub_private_repo`: None
- `hub_always_push`: False
- `gradient_checkpointing`: False
- `gradient_checkpointing_kwargs`: None
- `include_inputs_for_metrics`: False
- `include_for_metrics`: []
- `eval_do_concat_batches`: True
- `fp16_backend`: auto
- `push_to_hub_model_id`: None
- `push_to_hub_organization`: None
- `mp_parameters`: 
- `auto_find_batch_size`: False
- `full_determinism`: False
- `torchdynamo`: None
- `ray_scope`: last
- `ddp_timeout`: 1800
- `torch_compile`: False
- `torch_compile_backend`: None
- `torch_compile_mode`: None
- `dispatch_batches`: None
- `split_batches`: None
- `include_tokens_per_second`: False
- `include_num_input_tokens_seen`: False
- `neftune_noise_alpha`: None
- `optim_target_modules`: None
- `batch_eval_metrics`: False
- `eval_on_start`: False
- `use_liger_kernel`: False
- `eval_use_gather_object`: False
- `average_tokens_across_devices`: False
- `prompts`: None
- `batch_sampler`: batch_sampler
- `multi_dataset_batch_sampler`: round_robin

</details>

### Training Logs
| Epoch  | Step | cosine_ndcg@10 |
|:------:|:----:|:--------------:|
| 1.0    | 22   | 0.8768         |
| 2.0    | 44   | 0.9484         |
| 2.2727 | 50   | 0.9330         |
| 3.0    | 66   | 0.9276         |
| 4.0    | 88   | 0.9484         |
| 4.5455 | 100  | 0.9330         |
| 5.0    | 110  | 0.9638         |
| 6.0    | 132  | 0.9638         |
| 6.8182 | 150  | 0.9638         |
| 7.0    | 154  | 0.9638         |
| 8.0    | 176  | 0.9484         |
| 9.0    | 198  | 0.9484         |
| 9.0909 | 200  | 0.9484         |
| 10.0   | 220  | 0.9484         |


### Framework Versions
- Python: 3.11.11
- Sentence Transformers: 3.3.1
- Transformers: 4.48.3
- PyTorch: 2.5.1+cu124
- Accelerate: 1.3.0
- Datasets: 3.3.2
- Tokenizers: 0.21.0

## Citation

### BibTeX

#### Sentence Transformers
```bibtex
@inproceedings{reimers-2019-sentence-bert,
    title = "Sentence-BERT: Sentence Embeddings using Siamese BERT-Networks",
    author = "Reimers, Nils and Gurevych, Iryna",
    booktitle = "Proceedings of the 2019 Conference on Empirical Methods in Natural Language Processing",
    month = "11",
    year = "2019",
    publisher = "Association for Computational Linguistics",
    url = "https://arxiv.org/abs/1908.10084",
}
```

#### MatryoshkaLoss
```bibtex
@misc{kusupati2024matryoshka,
    title={Matryoshka Representation Learning},
    author={Aditya Kusupati and Gantavya Bhatt and Aniket Rege and Matthew Wallingford and Aditya Sinha and Vivek Ramanujan and William Howard-Snyder and Kaifeng Chen and Sham Kakade and Prateek Jain and Ali Farhadi},
    year={2024},
    eprint={2205.13147},
    archivePrefix={arXiv},
    primaryClass={cs.LG}
}
```

#### MultipleNegativesRankingLoss
```bibtex
@misc{henderson2017efficient,
    title={Efficient Natural Language Response Suggestion for Smart Reply},
    author={Matthew Henderson and Rami Al-Rfou and Brian Strope and Yun-hsuan Sung and Laszlo Lukacs and Ruiqi Guo and Sanjiv Kumar and Balint Miklos and Ray Kurzweil},
    year={2017},
    eprint={1705.00652},
    archivePrefix={arXiv},
    primaryClass={cs.CL}
}
```

<!--
## Glossary

*Clearly define terms in order to be accessible across audiences.*
-->

<!--
## Model Card Authors

*Lists the people who create the model card, providing recognition and accountability for the detailed work that goes into its construction.*
-->

<!--
## Model Card Contact

*Provides a way for people who have updates to the Model Card, suggestions, or questions, to contact the Model Card authors.*
-->